<DOC>
	<DOCNO>NCT02322333</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , randomize , multi-center study . Subjects agree participate study meet entry criterion assess screen visit , begin 28 day baseline period confirm diagnosis , well establish baseline migraine characteristic . During baseline period , subject continue treat migraine usual , simply record information daily headache diary . Subjects , complete baseline , continue meet entrance criterion eligible enter treatment phase randomize accord Clinvest generate randomization schedule . Approximately 142 subject ( 71 subject per arm ) randomize enter treatment phase receive MLD10 placebo 1:1 design 6 United States site . Diary assessment collect study medication adherence , pain severity , headache symptom , acute medication usage , unusual symptom . Serum sample collect analyzed ionized magnesium , electrolytes , creatinine .</brief_summary>
	<brief_title>MLD10 Prevention Migraine Adults</brief_title>
	<detailed_description>This multi-center , double-blind , randomize , placebo-controlled , parallel study MLD10 prevention migraine headache . The study population consist approximately 142 male female subject 18 65 year age frequent episodic migraine define International Classification Headache Disorders-3beta criterion . Two MLD10 ( 243 mg ( milligram ) elemental magnesium ) placebo caplets take twice daily total daily dose 486 mg. VISIT 1 - SCREENING The follow complete Visit 1 : 1 . Obtain write Informed Consent . The informed consent obtain accordance Good Clinical Practices ( GCP ) applicable regulatory requirement subject prior participation study . 2 . Verify Inclusion/Exclusion Criteria . Subjects meet inclusion none exclusion criterion . 3 . Obtain demographic ( race , ethnicity , sex , date birth ) 4 . Obtain medical , medication , headache history . Data collect include medical history diagnosis , age onset migraine pertinent migraine/headache history , history acute prophylactic headache medication within past 30 day , history recent/concomitant medication . 5 . Obtain date last menstrual cycle perform urine pregnancy test , appropriate . Results pregnancy test must negative continue study . 6 . Perform physical neurological examination . 7 . Measure vital sign ( height , weight , rest heart rate , blood pressure ) . 8. Review Baseline Headache Diary . Subjects instruct complete daily online headache diary . Assessments capture start/stop time , severity , associate symptom , use rescue medication , unusual symptom . 9 . Administer Columbia-Suicide Severity Rating Scale ( C-SSRS ) . 10 . Schedule Visit 2 . VISIT 2 - RANDOMIZATION 1 . Verify Inclusion/Exclusion Criteria . Subjects must continue meet inclusion ( include ≥ 3 day migraine baseline ) none exclusion criterion . 2 . Perform urine pregnancy test , appropriate . Results pregnancy test must negative continue study . 3 . Measure vital sign ( weight , rest heart rate , blood pressure ) . 4 . Record change concomitant medication . 5 . Record Serious Adverse Events ( SAE ) since sign Informed Consent . 6. Review Baseline Headache Diary completeness continue eligibility . 7 . Randomize subject 8. Review Month 1 Headache Diary instruction ( instruction discuss Baseline Headache Diary ) . 9 . Dispense Month 1 study medication . Subjects instruct take study medication , prohibit medications/foods , dosage limitation study medication , storage requirement . Subjects instructed return used/partially used/unused study medication next office visit medication reconciliation perform ensure compliance least 80 % . Subjects comply 80 % level withdrawn , unless otherwise approve Sponsor and/or Clinvest . ( Estimated &lt; 10 % ) 10 . Administer C-SSRS . 11 . Administer MIDAS . 12 . Collect serum sample electrolytes , creatinine , ionize Mg. 13 . Schedule Visit 3 . VISIT 3 - END OF TREATMENT PERIOD MONTH 1 1 . Record change concomitant medication . 2 . Record Non-Serious Adverse Events ( NSAE ) and/or SAEs . 3 . Perform urine pregnancy test , appropriate . Results pregnancy test must negative continue study . 4 . Measure vital sign ( weight , rest heart rate , blood pressure ) . 5. Review Month 1 Headache Diary completeness . 6. Review instruction Month 2 Headache Diary ( instruction discuss Month 1 Headache Diary ) . 7 . Collect Month 1 unused study medication use packaging . Confirm 85 % compliance medication usage per study protocol . 8 . Dispense Month 2 study medication review dosage limitation study medication , storage requirement , return used/partially used/unused study medication next office visit . 9 . Perform drug accountability . 10 . Administer C-SSRS . 11 . Collect serum sample electrolytes , creatinine , ionize Mg. 12 . Schedule Visit 4 . VISIT 4 - END OF TREATMENT PERIOD MONTH 2 1 . Record change concomitant medication . 2 . Record NSAEs/SAEs . 3 . Perform urine pregnancy test , appropriate . Results pregnancy test must negative continue study . 4 . Measure vital sign ( weight , rest heart rate , blood pressure ) . 5. Review Month 2 Headache Diary completeness . 6. Review instruction Month 3 Headache Diary ( instruction discuss Month 2 Headache Diary ) . 7 . Collect Month 2 unused study medication use packaging . Confirm 85 % compliance medication usage per study protocol . 8 . Dispense Month 3 study medication review dosage limitation study medication , storage requirement , return used/partially used/unused study medication next office visit . 9 . Perform drug accountability . 10 . Administer C-SSRS . 11 . Collect serum sample electrolytes , creatinine , ionize Mg. 12 . Schedule Visit 5 . VISIT 5 - END OF TREATMENT PERIOD MONTH 3 1 . Record change concomitant medication . 2 . Record NSAEs/SAEs . 3 . Perform urine pregnancy test , appropriate . 4 . Measure vital sign ( weight , rest heart rate , blood pressure ) 5 . Perform physical/neurological examination . 6 . Collect Month 4 unused study medication use packaging . 7 . Perform drug accountability . 8 . Administer SGIC &amp; complete PGIC . 9 . Administer MIDAS . 10 . Administer C-SSRS . 11 . Collect serum sample electrolytes , creatinine , ionize Mg. 12 . Exit subject .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1. male female , otherwise good health , 18 65 year age . 2. history frequent episodic migraine ( 314 migraine day per month ) ( without aura ) accord International Classification Headache Disorders3beta least 3 month . 3. onset migraine age 50 . 4. stable history migraine least 3 month prior screen . 5. currently take migraine preventive take preventive least 30 day prior screen agrees start , stop , change medication and/or dosage study period . 6. female childbearing potential , negative urine pregnancy test Visits 15 us , agrees use , duration study , medically acceptable form contraception list : complete abstinence intercourse 2 week prior administration study drug , throughout study , 7 day completion premature discontinuation study ; surgically sterile ( hysterectomy tubal ligation otherwise incapable pregnancy ) ; sterilization male partner monogamous relationship ; intrauterine device publish data show low expected failure rate le 1 % per year ; double barrier method ( i.e. , 2 physical barrier OR 1 physical barrier plus spermicide ) least 1 month prior Visit 1 throughout study ; hormonal contraceptive least 3 month prior Visit 1 throughout study . 7. completion online diary must ≥ 80 % compliance , unless otherwise approve Sponsor and/or Clinvest . 1. unable understand study requirement , informed consent , complete headache record require per protocol . 2. pregnant , actively try become pregnant , breastfeed . 3. diagnose International Classification Headache Disorders3beta criterion Chronic Migraine within 3 month prior screen , time screening , and/or baseline period . 4. experience follow migraine variant : basilar migraine , aura without headache , familial hemiplegic migraine , complicate migraine , ophthalmoplegic migraine retinal migraine within last year . 5. history medication overuse headache ( MOH ) ( Appendix II ) 3 month prior study enrollment baseline phase . 6. history medication overuse ( MO ) ergotamine , triptans , opioids , analgesic , NSAIDS combination therapy , define ICHD3beta criterion and/or MO baseline period . 7. history substance abuse and/or dependence , opinion Investigator . 8. history impaired renal function , investigator 's opinion , contraindicate participation study . 9. unstable neurological condition significantly abnormal neurological examination focal sign sign increase intracranial pressure . 10. suffers serious illness , unstable medical condition , one could require hospitalization , could increase risk adverse event . 11. significant risk suicide , define `` yes '' answer follow question ColumbiaSuicide Severity Rating Scale ( CSSRS ) , either screen visit ( assess prior 12 month ) visit 2 ( assess time since screen visit ) : 1 . Questions 4 5 suicidal ideation section 2 . Any question item suicidal behavior section 12. psychiatric disorder psychotic feature , and/or psychiatric disorder stable well control , would interfere ability complete study activity . 13. hypersensitivity , intolerance , contraindication use magnesium Llactate dehydrate component . 14. receive investigational agent within 30 day prior Visit 1 . 15. plan participate another clinical study time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>